Tumor Markers AFP, Beta-hCG and LDH Explained
AFP, beta-hCG and LDH are blood tumour markers used in suspected and confirmed testicular germ-cell cancer. They help with diagnosis, staging, prognosis, monitoring treatment response and detecting relapse, but none is a perfect “cancer test.” Markers should be measured before radical orchidectomy and repeated afterwards, allowing for their biological half-lives. A normal marker result does not rule out testicular cancer. An elevated AFP is especially important because pure seminoma should not produce AFP; if AFP is genuinely elevated, the tumour is managed as non-seminomatous disease even if part of the pathology looks like seminoma.
At a glance
| Marker | What it can indicate | Important limitation |
|---|---|---|
| AFP | Often elevated in non-seminomatous germ-cell tumours | Pure seminoma does not produce AFP |
| Beta-hCG | Can rise in non-seminoma and some seminomas | Other conditions can occasionally elevate hCG |
| LDH | Rough marker of tumour burden/prognosis | Nonspecific; rises in many non-cancer conditions |
AFP (alpha-fetoprotein)
AFP is produced by yolk-sac elements and some embryonal carcinomas. It is not produced by pure seminoma or pure choriocarcinoma. Liver disease and other non-testicular conditions can also raise AFP, so results must be interpreted in context.
Beta-hCG (human chorionic gonadotropin)
Beta-hCG can be produced by choriocarcinoma and other non-seminomatous components, and it can also be elevated in a proportion of seminomas. Very high values can be associated with symptoms such as breast tenderness. Persistent elevation after orchidectomy suggests residual disease unless another cause is found.
LDH (lactate dehydrogenase)
LDH is less specific than AFP or beta-hCG. It can rise with tissue injury, liver disease, haemolysis and many other conditions. In germ-cell cancer it contributes to prognostic classification and may reflect tumour burden, but a single isolated mild elevation should not be overinterpreted.
Why markers are repeated after orchidectomy
After the tumour is removed, marker levels should fall according to expected half-lives—AFP roughly over several days and hCG more quickly. Failure to fall appropriately or a new rise can indicate persistent/metastatic cancer. Normalisation does not guarantee that no microscopic disease remains.
Markers during chemotherapy and surveillance
Serial marker trends are more informative than one result. Falling levels support treatment response; a confirmed rise may indicate progression or relapse. Imaging and clinical findings remain essential because some tumours do not secrete markers.
Each marker behaves differently
AFP is produced by non-seminomatous elements such as yolk-sac tumour and should not be elevated by pure seminoma. Beta-hCG can rise in both seminoma and non-seminoma. LDH is much less specific and may increase for many non-cancer reasons, so it is usually a supporting marker rather than a standalone diagnostic test.
Half-lives matter after orchidectomy
Markers should fall after removal of the primary tumour according to their expected biological half-lives. A value that remains elevated is interpreted as a trend, not a single isolated number. Failure to fall appropriately can indicate persistent microscopic disease even when CT does not show a visible metastasis.
False positives are clinically important
Liver disease can raise AFP; hypogonadism, marijuana use and laboratory interference can affect hCG interpretation; haemolysis and many illnesses can elevate LDH. Borderline unexpected results should often be repeated and correlated with the clinical picture before declaring relapse.
A “normal marker panel” does not clear the testicle
AFP, beta-hCG and LDH support diagnosis, staging and follow-up, but none is a screening test that can exclude cancer. Seminoma should not raise AFP; if AFP is convincingly elevated, a non-seminomatous component must be considered even when the pathology appears seminomatous. Marker half-lives after orchidectomy are also important: a falling value can be expected, while failure to fall appropriately may indicate persistent disease and can change stage or treatment.
When to seek earlier medical review
Marker results should be reviewed promptly if they remain elevated or fail to fall as expected after orchidectomy. Do not interpret a single LDH value in isolation; infection, liver disease, haemolysis and other conditions can affect it.
Emergency warning signs
- Sudden severe testicular pain, especially with nausea (torsion must be excluded urgently)
- Rapidly increasing scrotal swelling or severe pain
- Breathing difficulty, severe headache or neurological symptoms in a patient with known advanced cancer
- Fever or worsening wound redness after surgery
What to bring to your consultation
- AFP, beta-hCG and LDH with dates
- Orchidectomy pathology if done
- CT staging reports
- Previous marker values to assess trend
Questions to ask your doctor
- Which marker is abnormal and is that pattern compatible with the pathology?
- Is the post-orchidectomy fall appropriate for the marker half-life?
- Could a non-cancer condition explain this borderline result?
FAQs
Can all three markers be normal in testicular cancer?
Yes. Normal AFP, beta-hCG and LDH do not exclude testicular cancer, especially seminoma.
Does elevated AFP mean I definitely have testicular cancer?
No. AFP can rise in liver disease and other malignancies. It must be interpreted with ultrasound, examination and clinical context.
Why are markers taken before surgery?
Pre-orchidectomy values are needed for staging and later comparison.
Can I use tumour markers instead of scans during follow-up?
No. Markers complement, but do not replace, appropriate imaging and clinical review.
Related reading
- Testicular Cancer: Symptoms and Treatment
- Painless Testicular Lump: When to Worry
- Radical Orchidectomy Explained
- Testicular Cancer and Fertility
- Urologist in Latur
References
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/testicular-cancer/chapter/diagnostic-evaluation
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Disease Management https://uroweb.org/guidelines/testicular-cancer/chapter/disease-management
- European Association of Urology (EAU). Testicular Cancer Guidelines, 2026. Follow-up After Curative Therapy https://uroweb.org/guidelines/testicular-cancer/chapter/followup-after-curative-therapy
- National Cancer Institute. Testicular Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq